Nov 24, 2022
Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is publ...
Read More...
DAWNZERA’s EU Approval Strengthens the Hereditary Angioedema Treatment Landscape
Jan 30, 2026
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
The Dynamic Landscape of Myelofibrosis Treatment: A 2024 Perspective
Jun 10, 2024
Newsletter/Whitepaper